September 16, 2018 - By Carol Mulligan

Proteon Therapeutics, Inc. (NASDAQ:PRTO) Logo


PROTEON THERAPEUTICS INC (NASDAQ:PRTO) institutional sentiment decreased to 0.86 in Q2 2018. Its down -0.02, from 0.88 in 2018Q1. The ratio turned negative, as 6 active investment managers increased and started new equity positions, while 7 sold and reduced stakes in PROTEON THERAPEUTICS INC. The active investment managers in our partner’s database now hold: 7.28 million shares, up from 7.27 million shares in 2018Q1. Also, the number of active investment managers holding PROTEON THERAPEUTICS INC in their top 10 equity positions was flat from 3 to 3 for the same number . Sold All: 6 Reduced: 1 Increased: 4 New Position: 2.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. The company has market cap of $39.00 million. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. It currently has negative earnings.

The stock increased 2.33% or $0.05 during the last trading session, reaching $2.2. About 10,798 shares traded. Proteon Therapeutics, Inc. (NASDAQ:PRTO) has risen 59.26% since September 16, 2017 and is uptrending. It has outperformed by 43.64% the S&P500.

Analysts await Proteon Therapeutics, Inc. (NASDAQ:PRTO) to report earnings on November, 6. They expect $-0.29 earnings per share, up 73.15 % or $0.79 from last year’s $-1.08 per share. After $-0.28 actual earnings per share reported by Proteon Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 3.57 % negative EPS growth.

Abingworth Llp holds 2.77% of its portfolio in Proteon Therapeutics, Inc. for 2.02 million shares. Mpm Asset Management Llc owns 983,381 shares or 0.93% of their US portfolio. Moreover, Deer Vii & Co. Ltd. has 0.92% invested in the company for 315,101 shares. The Massachusetts-based Ra Capital Management Llc has invested 0.21% in the stock. Boothbay Fund Management Llc, a New York-based fund reported 80,011 shares.

Proteon Therapeutics, Inc. (NASDAQ:PRTO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.